Communiqués Baudax Bio, Inc.

Actions

BXRXQ

US07160F4046

Temps Différé OTC Markets Autres places de cotation 20:44:58 17/06/2024			Varia. 5j.	Varia. 1 janv.
0,0098 ^USD	+1,03%		+55,56%	-55,45%

17/06	Première demande d'extension de la période d'exclusivité déposée par Baudax Bio, Inc.	CI
22/02	Baudax Bio, Inc. a déposé une demande d'ouverture de procédure de faillite	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Baudax Bio : Change in Certifying Accountants - Form 8-K	25/10/23	PU
Baudax Bio Announces Corporate Update	18/10/23	AQ
Baudax Bio : Corporate Overview	06/10/23	PU
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors	28/09/23	AQ
Baudax Bio : Corporate Overview	14/09/23	PU
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference	07/09/23	AQ
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock	23/08/23	AQ
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules	17/08/23	AQ
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update	16/08/23	AQ
Baudax Bio : Corporate Overview	18/07/23	PU
Watchlist Alert: Nasdaq Stocks Under $1 Experience Volume Breakouts: KAVL, BXRX, RMED, SMX	07/07/23	AQ
Baudax Bio Acquires TeraImmune, Inc.	30/06/23	AQ
Baudax Bio : Management’s Discussion and Analysis of Financial Condition and Results of Operations - Form 8-K	28/06/23	PU
BAUDAX BIO, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	15/06/23	AQ
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000	07/06/23	AQ
Baudax Bio Announces Date of Reconvened Annual Meeting	06/06/23	AQ
BAUDAX BIO, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	19/05/23	AQ
Baudax Bio Reports First Quarter Financial Results and Provides Business Update	12/05/23	AQ
BAUDAX BIO, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	12/05/23	AQ
Baudax Bio : Corporate Overview	10/05/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Baudax Bio, Inc.

Actions

BXRXQ

US07160F4046

Communiqués

Filtres